MediWound Ltd. (MDWD) EPS Estimated At $-0.13

Analysts expect MediWound Ltd. (NASDAQ:MDWD) to report $-0.13 EPS on May, 9.They anticipate $0.04 EPS change or 23.53 % from last quarter’s $-0.17 EPS. After having $-0.06 EPS previously, MediWound Ltd.’s analysts see 116.67 % EPS growth. The stock decreased 1.47% or $0.07 during the last trading session, reaching $4.7. About 65,195 shares traded. MediWound Ltd. (NASDAQ:MDWD) has risen 13.85% since May 8, 2018 and is uptrending. It has outperformed by 9.48% the S&P500.

MediWound Ltd. (NASDAQ:MDWD) Ratings Coverage

Among 3 analysts covering Mediwound (NASDAQ:MDWD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mediwound had 5 analyst reports since March 12, 2019 according to SRatingsIntel. The company was maintained on Tuesday, March 12 by Oppenheimer. The rating was maintained by SunTrust on Tuesday, March 12 with “Buy”. The stock of MediWound Ltd. (NASDAQ:MDWD) has “Buy” rating given on Tuesday, March 12 by Wells Fargo. On Monday, March 25 the stock rating was maintained by Oppenheimer with “Buy”.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. The company has market cap of $127.74 million. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. It currently has negative earnings. The firm also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds.

More notable recent MediWound Ltd. (NASDAQ:MDWD) news were published by: which released: “Apr 24, 2019 – Oppenheimer & Co Inc Buys SPDR S&P 500, FedEx Corp, Walmart Inc, Sells iShares 20+ Year Treasury Bond ETF, AbbVie Inc, SPDR Select Sector Fund – Financial –” on April 24, 2019, also with their article: “MediWound Expands Its NexoBrid® Phase 3 Children Innovation Debridement Study (CIDS) to the U.S. – GlobeNewswire” published on June 19, 2018, published: “MediWound: Doubling Sales Even Before Likely FDA Approval – Seeking Alpha” on November 21, 2017. More interesting news about MediWound Ltd. (NASDAQ:MDWD) were released by: and their article: “Mustang Bio leads healthcare gainers; Eiger BioPharmaceuticals and OncoMed Pharmaceuticals among losers – Seeking Alpha” published on April 18, 2019 as well as‘s news article titled: “Will MediWound (MDWD) Report Negative Q1 Earnings? What You Should Know – Nasdaq” with publication date: May 02, 2019.

MediWound Ltd. (NASDAQ:MDWD) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.